| HHS/NIH Small Business Town Hall |
Meeting/ Workshop |
CDC, FDA |
OD/DPCPSI/ORIP, OD/OER |
HHS/NIH Small Business Town Hall meetings organized by the Small Business Education and Entrepreneurial Development (SEED) at OER, OD. Attendance includes all Small Business Representatives (HHS Small Business Program Managers) of the NIH-ICOs, CDC and FDA. Meetings are three to four times a year and are organized to inform about news, updates, program reauthorization, directives changes/interpretation, budgets and initiatives (NOFOs) related to the Small Business program. |
| HHS/OGA Global Gender Equality and Reproductive Rights |
Committee, Work group, Advisory group, or Task Force |
OGA |
|
This group meets monthly and reviews policies on gender equality and reproductive rights that have a global impact. |
| HHS: Continuity Management Council |
Committee, Work group, Advisory group, or Task Force |
OS, CDC, CMS, FDA, IHS |
OD/OM, OD/OM/ORS |
This is a monthly meeting led by the HHS Administration for Strategic Preparedness and Response (ASPR) that brings together all HHS operating divisions to coordinate and discuss continuity plans and exercises. |
| HIV Clinical Guidelines Working Groups of OARAC |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA, HRSA |
NIAID, NICHD, NLM, OD/DPCPSI, OD/DPCPSI/OAR |
There are five Office of AIDS Research Advisory Council (OARAC) Working Groups to maintain updated federally approved clinical practice guidelines for HIV. The five working groups are the 1) Panel on Antiretroviral Guidelines for Adults and Adolescents, 2) Panel on Opportunistic Infections in Adults and Adolescents with HIV, 3) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, 4) Panel for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV, and 5) Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission. The HIV Clinical Guidelines Panels update guidelines for HIV/AIDS care providers with the most current information on combination antiretroviral therapy, treatment and prevention of opportunistic infections for people with HIV; the prevention of perinatal HIV transmission; and the safety and efficacy of HIV therapies. |
| HIV/AIDS Cancer Match Study |
Research Initiative |
CDC |
NCI |
A study linking HIV and cancer registries in multiple US regions to evaluate the spectrum of cancer risk and outcomes in people living with HIV |
| Home and Community-Based Services Federal Opportunities Regarding Workforce and Research Data (HCBS FORWARD) Committee |
Committee, Work group, Advisory group, or Task Force |
ASPE, CMS |
NIA |
The Home and Community-Based Services Federal Opportunities Regarding Workforce and Research Data (HCBS FORWARD) Committee identifies, and makes recommendations on, key policy questions on the HCBS workforce to establish data priorities, analyze existing data sources on this workforce, and identify ways to fill critical gaps in knowledge. |
| HOPE Act NPRM Working Group |
Committee, Work group, Advisory group, or Task Force |
CDC, HRSA, OASH |
NIAID |
HOPE Act NPRM Working Group meets at least biweekly to develop new policy rule making for the HOPE Act (2013) for the Secretary |
| HRIT Modernization IPT |
Committee, Work group, Advisory group, or Task Force |
OS |
OD/OCIO |
HHS is working with NIH HR Stakeholders and NIH EA to rationalize NIH HR applications to HHS HR application |
| Human Milk Composition Initiative |
Committee, Work group, Advisory group, or Task Force |
FDA, OASH |
NIEHS, OD/DPCPSI/ODS, OD/ECHO |
The Human Milk Composition Initiative is a U.S.-Canada collaboration with subject matter experts from HHS, the U.S. Department of Agriculture, and other U.S. and Canadian agencies that coordinates across many entities to share information on human milk composition data availability for use by programs focused on maternal and child health. |
| IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing |
Other |
FDA |
NIAID |
This collaboration will allow the development of in vitro organ on a chip technology for modeling of SARS-CoV-2 infection, identification of biomarkers and transcriptomic and tissue expression imaging by MIBI/CODEX. The data collected from the organ on a chip systems will then be compared to ongoing analysis of human clinical samples and parallel testing in animal models of COVID. |